Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Russo

Showing results (381-390 of 419) with videos related to

Pageof 42
Sort By:
JAMA Oncology|May 29, 2025
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung CancerArianna Marinello, Maria Rosa Ghigna, Julia K Rotow, et al.
Frontiers in Immunology|February 2, 2024
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern ItalyVito Longo, Carminia Maria Della Corte, Alessandro Russo, et al.
Lung Cancer (Amsterdam, Netherlands)|December 29, 2023
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access programFrancesco Passiglia, Maria Lucia Reale, Giuseppe Lo Russo, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 18, 2026
Monotherapy vs combination therapy for Enterococcus faecalis bacteremia: a target trial emulationMichele Bartoletti, Elena Rosselli Del Turco, Linda Bussini, et al.
Expert Opinion on Biological Therapy|February 4, 2020
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving NivolumabFrancesco Pantano, Marco Russano, Alfredo Berruti, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 26, 2026
Clinical utility of the DENOVA score for predicting infective endocarditis in Enterococcus faecalis bacteremia: external validation with decision curve analysisBenedetta Varisco, Daniele Piovani, Elena Rosselli Del Turco, et al.
Targeted Oncology|April 5, 2023
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort StudyDiego F Chamorro, Andrés F Cardona, July Rodríguez, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 6, 2025
Corrigendum to "Team-based, hybrid, or standard of care? Organizational models of tuberculosis care on tuberculosis outcomes in eleven Italian hospital" [Clin Microbiol Infect (2025) 31(12) 2033-2040]Giacomo Guido, Francesco Di Gennaro, Francesco Cavallin, et al.
Cancer Treatment and Research Communications|February 18, 2026
Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trialChiara Mattioli, Emanuela Olmetto, Marco Banini, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2025
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS databaseMaria Lucia Reale, Daniela Scattolin, Antonio Vitale, et al.
Pageof 42

Showing results (381-390 of 419) with videos related to

Sort By:
Pageof 42
JAMA Oncology|May 29, 2025
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung CancerArianna Marinello, Maria Rosa Ghigna, Julia K Rotow, et al.
Frontiers in Immunology|February 2, 2024
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern ItalyVito Longo, Carminia Maria Della Corte, Alessandro Russo, et al.
Lung Cancer (Amsterdam, Netherlands)|December 29, 2023
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access programFrancesco Passiglia, Maria Lucia Reale, Giuseppe Lo Russo, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 18, 2026
Monotherapy vs combination therapy for Enterococcus faecalis bacteremia: a target trial emulationMichele Bartoletti, Elena Rosselli Del Turco, Linda Bussini, et al.
Expert Opinion on Biological Therapy|February 4, 2020
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving NivolumabFrancesco Pantano, Marco Russano, Alfredo Berruti, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 26, 2026
Clinical utility of the DENOVA score for predicting infective endocarditis in Enterococcus faecalis bacteremia: external validation with decision curve analysisBenedetta Varisco, Daniele Piovani, Elena Rosselli Del Turco, et al.
Targeted Oncology|April 5, 2023
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort StudyDiego F Chamorro, Andrés F Cardona, July Rodríguez, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 6, 2025
Corrigendum to "Team-based, hybrid, or standard of care? Organizational models of tuberculosis care on tuberculosis outcomes in eleven Italian hospital" [Clin Microbiol Infect (2025) 31(12) 2033-2040]Giacomo Guido, Francesco Di Gennaro, Francesco Cavallin, et al.
Cancer Treatment and Research Communications|February 18, 2026
Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trialChiara Mattioli, Emanuela Olmetto, Marco Banini, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2025
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS databaseMaria Lucia Reale, Daniela Scattolin, Antonio Vitale, et al.
Pageof 42